N-Acetyl Semax Amidate
Research OnlyAlso known as: NA-Semax, N-Acetyl Semax, Acetyl-Semax-Amidate, NASA-Semax
A chemically modified version of Semax with N-terminal acetylation and C-terminal amidation designed to enhance peptide stability. While parent Semax is approved in Russia for nootropic and neuroprotective applications, this specific modification has no independent clinical research.
Research Statistics
N-acetyl amidate modification of semax with no direct human studies; mechanism extrapolated from parent compound with no independent validation of this specific chemical modification.
Research Dossier
Overview
What is N-Acetyl Semax Amidate and what does the research say?
Mechanism of Action
The proposed mechanisms of N-Acetyl Semax Amidate are extrapolated entirely from parent compound Semax research. No direct studies exist on this modified form.
How It Works (Simplified)
N-Acetyl Semax Amidate is proposed to work through the same pathways as Semax, with enhanced stability from terminal modifications:
Parent Semax increases BDNF, NGF, and GDNF expression. Whether modifications preserve this activity is unknown.
Semax affects dopamine and serotonin systems. The modified form’s receptor affinity has never been tested.
Semax activates TrkB receptors for neuroplasticity. Impact of terminal modifications on binding is uncharacterized.
N-acetylation blocks aminopeptidases, C-amidation blocks carboxypeptidases. Actual half-life extension not measured.
Scientific Pathways
Neurotrophic Pathway (Extrapolated from Semax)
NA-Semax-Amidate (theoretical) → Same as Semax? → BDNF/NGF upregulation → TrkB activation
↓
Neuroplasticity & neuroprotectionDopaminergic Modulation (Extrapolated from Semax)
NA-Semax-Amidate (theoretical) → Dopamine system → Enhanced cognition/motivation
→ Serotonin system → Mood modulationKey Research: Dmitrieva VG et al. (Russia, 2008) demonstrated BDNF expression effects with Semax. PMID:17706034
Important Limitations
- Zero published studies on N-Acetyl Semax Amidate specifically
- All mechanisms extrapolated from parent Semax research
- Whether modifications preserve biological activity is untested
- No human pharmacokinetic data exists for this compound
Evidence-Chained Benefits
Evidence-Chained Benefits
Research findings linked to mechanisms and clinical outcomes
What to Expect
Timeline based on observations from published studies. Individual responses may vary.
No human data available. Based on parent Semax pharmacology: Acute cognitive effects may be noticed. Russian Semax studies suggest rapid onset of action. Whether modifications alter timeline is unknown.
Extrapolated from Semax: Neurotrophic factor expression changes may develop. Parent compound shows BDNF modulation in animal models within this timeframe. No data specific to NA-Semax-Amidate.
Based on general nootropic peptide research: Neuroplasticity effects may accumulate with continued use. No long-term studies exist for this modified compound.
Completely unknown. No studies have evaluated extended use of N-Acetyl Semax Amidate. Long-term safety and efficacy data do not exist.
Research-Based Observations
This timeline reflects observations from published clinical and preclinical studies. Individual responses may vary significantly. This is not a guarantee of effects or a dosing schedule. Consult qualified healthcare providers for personalized guidance.
Quality Checklist
Visual indicators to help evaluate N-Acetyl Semax Amidate product quality
Good Signs (6 indicators)
Warning Signs (5 indicators)
Bad Signs (6 indicators)
For Research Evaluation Only
These quality indicators are general guidelines based on typical peptide characteristics. Professional laboratory testing (HPLC, mass spectrometry) provides definitive quality verification. This checklist is for initial visual evaluation only.
Peptide Interactions
Known and theoretical interactions when combining N-Acetyl Semax Amidate with other peptides. Based on published research and mechanistic considerations.
Semax
SynergisticParent compound with identical core sequence. NA-Semax-Amidate is designed to extend duration of action through terminal modifications. No studies comparing direct combination.
Na-Selank-Amidate
CompatibleBoth are modified Russian nootropic peptides with different mechanisms (Semax: neurotrophic focus vs Selank: anxiolytic focus). Commonly discussed together but no interaction studies exist.
Selank
CompatibleDifferent mechanism profiles. Selank focuses on anxiolytic effects while Semax derivatives target cognitive enhancement. No known contraindications.
Research Note: Interaction data is based on published literature, mechanistic understanding, and theoretical considerations. Most peptide combinations lack direct clinical study. This information is for educational purposes only and does not constitute medical advice. Always consult qualified healthcare providers.
References
Key Studies Cited
Full reference list available on request. All citations link to PubMed for verification.
Methodology Note
This dossier synthesizes available evidence from peer-reviewed literature, regulatory documents, and clinical trial registries. Evidence strength ratings follow a modified GRADE approach.
For complete methodology details, see our Methodology page.
Important Disclaimer
This dossier is for educational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider before making health decisions.
Get Research Alerts
New dossiers and major study summaries delivered to your inbox. Evidence-graded, citation-backed research you can trust.
No spam. Unsubscribe anytime.
Compare N-Acetyl Semax Amidate
Related Peptides
Alixorexton
ALKS 2680, ALKS-2680
An oral orexin receptor 2 (OX2R) agonist developed by Alkermes for narcolepsy type 1 (NT1). Phase 2 clinical trials demonstrated improvements in excessive daytime sleepiness and cataplexy with once-daily dosing. Represents a novel approach to restore orexin signaling in patients who have lost orexin-producing neurons.
Cerebrolysin
FPF-1070, N-PEP-12, Renacenz
A porcine brain-derived peptide mixture approved in over 50 countries (Austria, Russia, China, Germany) for stroke, dementia, and traumatic brain injury. Contains neurotrophic peptide fragments mimicking BDNF, GDNF, NGF, and CNTF. NOT FDA-approved despite decades of international use. Mixed Phase 3 results but positive meta-analyses and widespread clinical adoption in Europe, Asia, and Latin America.
Cerluten
Brain cytamin, Cerebral peptides, A-5 brain peptides
A cytamin-class peptide supplement derived from brain tissue, part of the Russian bioregulator framework. Marketed as an oral supplement for cognitive support and neuroprotection. Contains peptide complexes rather than defined sequences. No Western clinical validation.
Cortexin
Cortexinum, Polypeptide brain extract, Bovine brain cortex polypeptides
A Russian neuropeptide complex derived from porcine or bovine cerebral cortex, approved in Russia and CIS countries for neurological conditions. Contains low molecular weight polypeptides (1,000-10,000 Da) with proposed neurotrophic and neuroprotective properties. NOT approved by FDA, EMA, or other Western regulatory agencies. Evidence comes primarily from Russian studies with limited Western validation.
Dihexa
PNB-0408, N-hexanoic-Tyr-Ile-(6) aminohexanoic amide
An angiotensin IV analog developed by Washington State University researchers, claimed to enhance cognition through HGF/c-Met signaling. Gained attention for extreme potency claims (10 million times more potent than BDNF), but evidence is limited to rodent studies from a single research group with no human clinical trials. Sold as a research chemical with unknown safety profile.
DSIP
Delta Sleep Inducing Peptide, Delta Sleep-Inducing Peptide, WAGGDASGE
A nonapeptide discovered in 1977 that was initially thought to induce delta wave sleep. Research has shown broader neuromodulatory effects including stress-protection and analgesia, though its role as an endogenous sleep factor remains controversial.